Prior authorization for biologic disease-modifying antirheumatic drugs: A description of US medicaid programs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prior authorization for biologic disease-modifying antirheumatic drugs: A description of US medicaid programs

Published:2008-11-15 Issue:11 Volume:59 Page:1611-1617
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Fischer Michael A.,Polinski Jennifer M.,Servi Amber D.,Agnew-Blais Jessica,Kaci Liljana,Solomon Daniel H.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference13 articles.

1. The pharmaceutical industry versus Medicaid: limits of state initiatives to control prescription-drug costs;Mello;N Engl J Med,2004

2. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review;Fischer;Med Care,2006

3. Impact of Medicaid prior authorization on angiotensin receptor blockers: can policy promote rational prescribing?;Fischer;Health Aff (Millwood),2007

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review;Journal of Managed Care & Specialty Pharmacy;2023-05

2. Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists;The American Journal of Managed Care;2023-04-20

3. Automated versus manual prior authorization for diabetes mellitus drugs: A retrospective study from Israel;DIGITAL HEALTH;2023-01

4. Insurance Status and Tumor Necrosis Factor Inhibitor Initiation Among Children With Juvenile Idiopathic Arthritis in the CARRA Registry;The Journal of Rheumatology;2022-12-15

5. Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study;Journal of Clinical Rheumatology and Immunology;2022-09-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3